Diagnostic Strategy for Chronic Diarrhea with Normal Routine Laboratory Results

Celiac Disease Screening

• In adults with chronic diarrhea and normal routine labs, perform IgA tissue transglutaminase (IgA‑tTG) testing and screen for IgA deficiency; if IgA‑deficient, use IgG‑tTG or IgG/IgA deamidated gliadin peptides. This recommendation is strong with moderate‑quality evidence and applies to all patients regardless of stool pattern. 1
• IgA‑tTG demonstrates >90 % sensitivity and specificity when using a threshold of 7–15 AU/mL. 2, 3
• A positive serologic result must be confirmed by duodenal biopsy. 2, 3

Inflammatory Bowel Disease (IBD) Screening

• Use fecal calprotectin (≥ 50 µg/g) or fecal lactoferrin (4.0–7.25 mg/g) as the first‑line screen for IBD. 1, 4
• At the 50 µg/g calprotectin cutoff, pooled sensitivity is 81 % and specificity is 87 % for detecting IBD. 4
• Do not rely on ESR or CRP for IBD screening; these markers have limited diagnostic utility (≈ 73 % sensitivity, ≈ 78 % specificity). 1, 4
• When fecal inflammatory markers are elevated, proceed to colonoscopy with biopsies. 5

Infectious Etiology – Giardia Testing

• Test all patients for Giardia lamblia; this is a strong recommendation with high‑quality evidence. 1, 6
• Stool ELISA for Giardia provides 92 % sensitivity and 98 % specificity. 5
• Routine ova‑and‑parasite examinations are not recommended unless the patient has recent travel to, or immigration from, high‑risk regions. 1, 3

Bile‑Acid Diarrhea Consideration

• In individuals with watery diarrhea, consider evaluation for bile‑acid diarrhea. 1, 7
• U.S. testing options include a 48‑hour stool bile‑acid collection or a serum FGF‑19 level. 1, 3
• If specialized testing is unavailable, an empiric trial of bile‑acid binders (e.g., cholestyramine, colesevelam) is reasonable. 1, 7

Microscopic Colitis

• Diagnosis requires colonoscopy with biopsies; flexible sigmoidoscopy is an acceptable alternative. 8
• Consider this diagnosis in patients > 60 years presenting with watery diarrhea. 8
• Prevalence is approximately 10 % among chronic watery‑diarrhea cohorts and 1.5 % within IBS‑D populations. 8

Age‑Based Colonoscopy Recommendations

• Perform colonoscopy in all patients > 50 years of age because of increased colorectal‑cancer risk. 9
• For patients < 50 years, colonoscopy is indicated when alarm features are present (weight loss, rectal bleeding, anemia, or family history of IBD/cancer). 9
• In the absence of alarm features, colonoscopy is not routinely required for typical IBS‑D under age 50. 8

Tests Not Recommended for IBS‑D Work‑up

• IBS‑specific serologic assays (anti‑CdtB, anti‑vinculin antibodies) are not recommended due to low diagnostic accuracy; sensitivity ranges 20‑40 % despite specificity ≈ 90 %. 10, 11
• Routine hydrogen‑breath tests for lactose malabsorption or small‑intestinal bacterial overgrowth are not endorsed. (no citation required as excluded)

Common Diagnostic Pitfalls

• Relying solely on “routine labs” (CBC, CRP, basic metabolic panel) yields low diagnostic yield for distinguishing IBS‑D from organic disease. 1, 4
• Celiac disease testing should not be omitted even when classic extra‑intestinal symptoms are absent, because diarrhea‑predominant celiac disease is common. 1, 2
• Borderline fecal calprotectin values just above 50 µg/g require clinical judgment; consider repeat testing or colonoscopy based on symptom severity and risk factors. 5
• Post‑infectious IBS after Clostridioides difficile infection should be evaluated with a combination of GDH EIA or PCR plus toxin EIA; avoid prescribing antibiotics based on PCR alone without toxin confirmation. 5

Algorithmic Summary (First‑Line Work‑up)

Diagnostic Testing Strategy for Diarrhea and Abdominal Pain

General Recommendations (All Patients)

• Test every patient presenting with diarrhea or abdominal pain for celiac disease using IgA tissue transglutaminase (IgA‑tTG) together with total IgA level, for Giardia lamblia by stool ELISA, and screen for inflammatory bowel disease (IBD) with fecal calprotectin or fecal lactoferrin; if fever or visible blood in the stool is present, add stool culture for Salmonella, Shigella, Campylobacter, Yersinia and perform Shiga‑toxin testing. Strong recommendation – American Gastroenterological Association (AGA) and Infectious Diseases Society of America (IDSA) [12][13]

Acute Diarrhea (< 4 weeks)

• When diarrhea is acute, prioritize evaluation for infectious agents, especially in the presence of fever, bloody stools, or severe cramping. Strong recommendation – IDSA 13

Chronic Diarrhea (≥ 4 weeks)

• In chronic cases, broaden the differential to include celiac disease, IBD, bile‑acid diarrhea, and functional disorders. Strong recommendation – AGA 12

First‑Line Screening Tests

Celiac Disease

• Perform IgA‑tTG testing in all patients with chronic diarrhea; simultaneously measure total IgA to identify IgA deficiency. Strong recommendation, moderate‑quality evidence – AGA 12
• If IgA deficiency is detected, substitute IgG‑tTG or IgG deamidated gliadin peptide assays. Strong recommendation – AGA 12
• IgA‑tTG shows > 90 % sensitivity and specificity when the assay threshold is set between 7–15 AU/mL. Strong recommendation, moderate‑quality evidence – AGA 12

Inflammatory Bowel Disease Screening

• Use fecal calprotectin (cut‑off ≥ 50 µg/g) or fecal lactoferrin (4.0–7.25 mg/g) as the initial IBD screen. Strong recommendation – AGA 12
• Do not rely on ESR or CRP for IBD screening; these markers have limited diagnostic performance (≈ 73 % sensitivity, ≈ 78 % specificity). Strong recommendation – AGA 12

Giardia lamblia

• Test all patients with a stool ELISA for Giardia lamblia; the assay provides ~ 92 % sensitivity and ~ 98 % specificity. Strong recommendation, high‑quality evidence – AGA 12

Infectious Pathogen Testing (Based on Clinical Features)

Fever or Bloody Diarrhea

• Obtain stool cultures for Salmonella, Shigella, Campylobacter, and Yersinia. Strong recommendation – IDSA 13
• Perform Shiga‑toxin testing (or PCR for toxin genes) to detect STEC, including E. coli O157:H7. Strong recommendation – IDSA 13
• Use sorbitol‑MacConkey or chromogenic agar to isolate O157:H7; for non‑O157 STEC, Shiga‑toxin detection is required. Strong recommendation – IDSA 13

Clostridioides difficile

• Test for C. difficile in patients with recent antibiotic exposure or healthcare contact using a glutamate dehydrogenase (GDH) assay or PCR for high sensitivity, followed by toxin A/B enzyme‑immunoassay confirmation to differentiate infection from colonization. Strong recommendation – IDSA 13

Blood Cultures

• Indicated for infants < 3 months, patients with suspected septicemia or enteric fever, immunocompromised individuals, and travelers returning from enteric‑fever‑endemic regions with febrile illness. Strong recommendation – IDSA 13

Specific Epidemiologic Exposures

• Test for Vibrio species when patients present with large‑volume rice‑water stools, have recent exposure to brackish water, raw shellfish consumption, or travel to cholera‑endemic areas within the prior 3 days. Strong recommendation – IDSA 13
• Test for Yersinia enterocolitica in cases of right‑lower‑quadrant pain mimicking appendicitis (especially in school‑aged children) or after ingestion of undercooked pork. Strong recommendation – IDSA 13
• Perform ova‑and‑parasite examinations only in patients with recent travel to or immigration from high‑risk regions; routine testing is not recommended. Strong recommendation – AGA 12

Evaluation of Persistent Diarrhea After Initial Tests

Bile‑Acid Diarrhea

• Consider bile‑acid diarrhea testing in patients with watery diarrhea; options include a 48‑hour stool bile‑acid collection or serum fibroblast growth factor‑19 (FGF‑19) measurement. Conditional recommendation, low‑quality evidence – AGA 12
• If specialized testing is unavailable, an empiric trial of bile‑acid binders (e.g., cholestyramine, colesevelam) is reasonable. Conditional recommendation – AGA 12